| __timestamp | Eli Lilly and Company | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 15746000 |
| Thursday, January 1, 2015 | 6533000000 | 13392000 |
| Friday, January 1, 2016 | 6452000000 | 9290000 |
| Sunday, January 1, 2017 | 6588100000 | 7672000 |
| Monday, January 1, 2018 | 5975100000 | 15293000 |
| Tuesday, January 1, 2019 | 6213800000 | 22648000 |
| Wednesday, January 1, 2020 | 6121200000 | 21864000 |
| Friday, January 1, 2021 | 6431600000 | 37318000 |
| Saturday, January 1, 2022 | 6440400000 | 48130000 |
| Sunday, January 1, 2023 | 6941200000 | 108146000 |
| Monday, January 1, 2024 | 8593800000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Eli Lilly and Company has consistently demonstrated robust financial management, with Selling, General, and Administrative (SG&A) expenses averaging around $6.4 billion annually. This reflects a stable investment in operational efficiency and market presence.
In contrast, Madrigal Pharmaceuticals, Inc., a smaller player, has shown a dynamic growth trajectory. From 2014 to 2023, Madrigal's SG&A expenses surged by over 580%, indicating aggressive expansion and increased market activities. This growth, from approximately $15 million to $108 million, underscores Madrigal's strategic push to enhance its competitive edge.
These trends highlight the contrasting strategies of a pharmaceutical giant and an emerging contender, offering valuable insights into their operational priorities and market positioning.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Xencor, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?